User profiles for Sarah Dawson
 | Sarah-Jane DawsonPeter MacCallum Cancer Centre, Melbourne Verified email at petermac.org Cited by 20823 |
[HTML][HTML] Analysis of circulating tumor DNA to monitor metastatic breast cancer
Background The management of metastatic breast cancer requires monitoring of the tumor
burden to determine the response to treatment, and improved biomarkers are needed. …
burden to determine the response to treatment, and improved biomarkers are needed. …
[HTML][HTML] The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes
The genomic landscape of breast cancer is complex, and inter-and intra-tumour heterogeneity
are important challenges in treating the disease. In this study, we sequence 173 genes in …
are important challenges in treating the disease. In this study, we sequence 173 genes in …
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Cancers acquire resistance to systemic treatment as a result of clonal evolution and
selection 1 , 2 . Repeat biopsies to study genomic evolution as a result of therapy are difficult, …
selection 1 , 2 . Repeat biopsies to study genomic evolution as a result of therapy are difficult, …
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA
…, D Gale, DWY Tsui, F Kaper, SJ Dawson… - Science translational …, 2012 - science.org
Plasma of cancer patients contains cell-free tumor DNA that carries information on tumor
mutations and tumor burden. Individual mutations have been probed using allele-specific …
mutations and tumor burden. Individual mutations have been probed using allele-specific …
[HTML][HTML] Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis …
…, MWR Reed, E Provenzano, SJ Dawson… - PLoS …, 2010 - journals.plos.org
Background Immunohistochemical markers are often used to classify breast cancer into
subtypes that are biologically distinct and behave differently. The aim of this study was to …
subtypes that are biologically distinct and behave differently. The aim of this study was to …
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Background We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification
for prognostication of patients with metastatic breast cancer by undertaking a pooled …
for prognostication of patients with metastatic breast cancer by undertaking a pooled …
[HTML][HTML] Multi-omic machine learning predictor of breast cancer therapy response
Breast cancers are complex ecosystems of malignant cells and the tumour microenvironment
1 . The composition of these tumour ecosystems and interactions within them contribute to …
1 . The composition of these tumour ecosystems and interactions within them contribute to …
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to
subvert T-cell-mediated immunosurveillance 1 , 2 . The success of therapies that disrupt PD-…
subvert T-cell-mediated immunosurveillance 1 , 2 . The success of therapies that disrupt PD-…
Non-genetic mechanisms of therapeutic resistance in cancer
JC Marine, SJ Dawson, MA Dawson - Nature Reviews Cancer, 2020 - nature.com
Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …
cancer treatment. Recent insights into the molecular determinants of acquired treatment …
BET inhibitor resistance emerges from leukaemia stem cells
Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies
that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that …
that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that …